Emerging Pathways
Navigene is reimagining diagnostic protocols and tools to enable faster, costefficient, integrated research, applicable for larger population. Our current focus of research is as follows.
Extraction of High Quality and Quantity of DNA from Dried Blood Spot and using RTPCR and, Sangers and NGS technique for further genetic studies

Navigene has developed a rapid, robust protocol for high-quality DNA extraction from dried blood spot (DBS) samples, enabling reliable downstream genetic testing. This breakthrough combines the simplicity of DBS collection and ambient transport with advanced molecular analysis, opening new possibilities for large-scale genetic assay development and population-based screening.
Multiplexing assay in a single sample and single test
Navigene is developing multiplex testing protocols to simultaneously detect HIV, HBsAg, T3/T4, TSH, HbA1c and other disease of public health importance from a single DBS sample. This approach leverages the ease of DBS collection and enables multi-analyte analysis without multiple venous draws, paving the way for integrated, simplified, large-scale screening and monitoring programs.

New Biomarker Discovery and Combinations

Navigene is researching disease prediction by studying biomarker and metabolite associations to identify the most discriminant indicators of pathology. By integrating early-stage biomarkers with clinical, demographic, socioeconomic, and phenotypic variables, Navigene is developing advanced predictive models. These approaches aim to detect intrauterine growth retardation (IUGR), assess risk of neonatal ICU admissions in preterm infants, and enable early interventions to reduce morbidity and mortality. Similar frameworks are being explored for ADHD, autism, infertility, and diabetic neuropathy. This integrative methodology advances precision medicine by uncovering novel biomarker associations and improving risk assessment and targeted care.